Singapore markets closed
Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
62,928.67 -1,565.59 (-2.43%) CMC Crypto 200
1,304.48 -92.06 (-6.59%)
Arbutus Biopharma Corporation (ABUS)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 491.88M |
| Enterprise value | 367.64M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 24.98 |
| Price/book (mrq) | 4.64 |
| Enterprise value/revenue | 20.27 |
| Enterprise value/EBITDA | -5.18 |
Trading information
Stock price history
| Beta (5Y monthly) | 2.09 |
| 52-week change 3 | 8.33% |
| S&P500 52-week change 3 | 22.36% |
| 52-week high 3 | 3.2900 |
| 52-week low 3 | 1.6900 |
| 50-day moving average 3 | 2.7650 |
| 200-day moving average 3 | 2.2724 |
Share statistics
| Avg vol (3-month) 3 | 1.41M |
| Avg vol (10-day) 3 | 983.64k |
| Shares outstanding 5 | 180.18M |
| Implied shares outstanding 6 | 180.18M |
| Float 8 | 115.8M |
| % held by insiders 1 | 23.34% |
| % held by institutions 1 | 43.92% |
| Shares short (15 Apr 2024) 4 | 5.17M |
| Short ratio (15 Apr 2024) 4 | 2.58 |
| Short % of float (15 Apr 2024) 4 | 3.69% |
| Short % of shares outstanding (15 Apr 2024) 4 | 2.87% |
| Shares short (prior month 15 Mar 2024) 4 | 4.13M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:5 |
| Last split date 3 | 04 Nov 2010 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -956.64% |
Management effectiveness
| Return on assets (ttm) | -28.70% |
| Return on equity (ttm) | -59.99% |
Income statement
| Revenue (ttm) | 18.14M |
| Revenue per share (ttm) | 0.11 |
| Quarterly revenue growth (yoy) | -65.70% |
| Gross profit (ttm) | N/A |
| EBITDA | -76.63M |
| Net income avi to common (ttm) | -72.85M |
| Diluted EPS (ttm) | -0.4400 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 126M |
| Total cash per share (mrq) | 0.7 |
| Total debt (mrq) | 8.72M |
| Total debt/equity (mrq) | 8.23% |
| Current ratio (mrq) | 5.87 |
| Book value per share (mrq) | 0.62 |
Cash flow statement
| Operating cash flow (ttm) | -85.94M |
| Levered free cash flow (ttm) | -51.58M |
© 2024 Yahoo. All rights reserved.